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Several comorbidities are associated to migraine. Recent meta-analyses have consis-
tently demonstrated a relationship between migraine and stroke, which is well-defined
for ischemic stroke and migraine with aura (MA), even stronger in females on oral contra-
ceptives or smokers. However, there seems to be no clear-cut association between stroke
in migraineurs and the common vascular risk factors, at least in the young adult popula-
tion. Migraineurs also run an increased risk of hemorrhagic stroke, while the association
between migraine and cardiovascular disease remains poorly defined. Another aspect is
the relationship between migraine and the presence of silent brain lesions. It has been
demonstrated that there is an increased frequency of ischemic lesions in the white mat-
ter of migraineurs, especially silent infarcts in the posterior circulation territory in patients
with at least 10 attacks per month. Although there is a higher prevalence of patent foramen
ovale (PFO) in migraineurs, the relationship between migraine and PFO remains controver-
sial and PFO closure is not a recommended procedure to prevent migraine. As an increased
frequency of cervical artery dissections has been observed in migrainous patients, it has
been hypothesized that migraine may represent a predisposing factor for cervical artery
dissection. There still remains the question as to whether migraine should be considered
a true “vascular disease” or if the comorbidity between migraine and cerebrovascular dis-
ease may have underlying shared risk factors or pathophysiological mechanisms. Although
further studies are required to clarify this issue, current evidence supports a clinical man-
agement where MA patients should be screened for other concomitant vascular risk factors
and treated accordingly.
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INTRODUCTION
Migraine and ischemic stroke (IS) are two highly prevalent dis-
eases. A relevant proportion of the population (up to 21% of
women, 6% of men) suffer from migraine attacks and 2/1,000 over
65 year-olds will have an IS (1–3). It has been common knowledge
for a long time in clinical practice that some migraine with aura
(MA) attacks may mimic cerebrovascular accident symptomatol-
ogy and that migraine aura may, although rarely, act as an acute
precipitant of an IS, the so-called “migrainous infarction.”
The case–control study by the Collaborative Group for the
Study of Stroke in Young Women (4) in 1975 was the first to
report a twofold risk for stroke in women affected by migraine
compared to community controls. Since then, a growing body
of evidence has demonstrated the association between migraine,
mostly MA, and IS. Moreover, MRI-based studies have demon-
strated that migraineurs have an increased frequency of subclin-
ical brain infarcts in the posterior circulation territory and that
female migraineurs have an increased risk for white matter lesions
(WMLs) (5, 6).
The question remains exactly to what extent there is a gener-
alized vasculopathy in migraine or vascular risk factors, genetic
traits, or other pathophysiological mechanisms, including the
patent foramen ovale (PFO), may play a role in linking migraine
to stroke.
This narrative review aimed at the examination of the
current evidence on the relationship between migraine and
cerebrovascular disease, mainly IS, focusing on the most intriguing
questions arising from this issue in the perspective of the clinical
practice.
MIGRAINE AS A RISK FACTOR FOR ISCHEMIC STROKE: THE
EVIDENCE
Three meta-analyses have consistently demonstrated a relation-
ship between these two highly prevalent and disabling conditions,
i.e., migraine and IS, where MA emerges as risk factor for stroke
(Table 1).
The meta-analysis carried out by Etminan et al. (7) postu-
lated that there was an increased risk of IS in individuals with
migraine: relative risk (RR) 2.16 (95% CI 1.89–2.48), with a higher
risk for migraineurs with MA, RR 2.27 (95% CI 1.61–3.19), than
those without, RR 1.83 (CI 95% 1.06–3.15), which was even more
evident in females taking oral contraceptives, RR 8.72 (95% CI
5.05–15.05).
Another meta-analysis, carried out by Schurks et al. (8),
included 25 heterogeneous studies and demonstrated that there
was a specific increase in the IS risk correlated to each type of
migraine (RR 1.73; 95% CI 1.31–2.29), with the highest values for
MA (RR 2.16; 95% CI 1.53–3.03), while the percentages were not
statistically significant for individuals without aura (RR 1.23; 95%
CI 0.90–1.69). Female migraineurs seem to be at the highest risk
(RR 2.08; 95% CI 1.13–3.84), those under 45 years of age (RR 2.65;
95% CI 1.41–4.97), and females on oral contraceptives (RR 7.02;
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Table 1 | Meta-analyses addressing the migraine-stroke association.
Stroke type No. of studies
included
Heterogeneity Migraine (M) Migraine with
aura (MA)
Migraine without
aura (MO)
Etminan et al. (7) Ischemic stroke 14 Total; 14 M,
7 MA, 6 MO
M: Ri=0.00 RR (95% CI)
2.16
(1.89–2.48)
RR (95% CI)
2.27
(1.61–3.19)
RR (95% CI)
1.83
(1.06–3.15)
MA Ri=0.49
MO Ri=0.60
Schurks et al. (8) Ischemic stroke 25 Total; 9 M,
8 MA, 8 MO
M: I2=65% RR (95% CI)
1.73
(1.31–2.29)
RR (95% CI)
2.16
(1.53–3.03)
RR (95% CI)
1.23
(0.9–1.69)
MA: I2=39%
MO: I2=39%
Spector et al. (9) Ischemic stroke 21 Total; 12 M,
7 MA, 6 MO
M: I2=63.5% OR (95% CI)
2.04
(1.72–2.76)
OR (95% CI)
2.25
(1.53–3.33)
OR (95% CI)
1.24
(0.86–2.43)
MA: I2=55.3%
MO: I2=47.1%
Sacco et al. (10) Hemorrhagic stroke 8 Total, 8 M,
3 MA, 3 MO
M I2=54.7% OR (95% CI)
1.48
(1.16–1.88)
OR (95% CI)
1.62
(0.87–3.03)
OR (95% CI)
1.39
(0.74–2.72)
MA I2=62.1%
MO I2=45.3%
Ri statistic: proportion of the total variance for between study variance: small values (<0.40) indicate lack of heterogeneity.
I2 statistic: percentage of total variation among studies due to heterogeneity rather than chance; 25% low heterogeneity, 50% medium, 75% high.
95% CI 1.51–32.68), in particular, if associated to the smoking
habit (RR 9.03; 95% CI 4.22–19.34) (8).
A more recent meta-analysis (9) took into consideration 21
studies, for a total of 622,381 patients (13 case–control studies and
8 cohort studies). They demonstrated a total adjusted odds ratio of
stroke in migraineurs vs. non-migraineurs of 2.04 (95% CI 1.72–
2.76), of 2.25 for MA vs. non-migraineurs (95% CI 1.53–3.33),
compared to 1.24 (95% CI 0.86–2.43) for migraineurs without
aura vs. non-migraineurs, for only the female gender it was 2.43
(CI 95% 1.80–3.27). However, when only the studies with a limited
bias were considered, the data for all the migraineurs vs. the non-
migraineurs produced an odds ratio, which was not statistically
significant: 1.24 (95% CI 0.86–1.79) (9).
FREQUENCY OF MIGRAINE ATTACKS AND STROKE RISK
Case–control studies suggest that the risk of IS increases along
with the increase in frequency of the migraine attacks.
One study on a total of 86 females with MA, aged from 20 to 44
and 214 control subjects, demonstrated that individuals with more
than 13 attacks per year have a 10-fold higher risk of stroke (11).
Another study, that compared 386 females with IS, aged from
15 to 49, to 614 control subjects without migraine, showed that
females who had more than 12 attacks per year with aura probably
run a higher IS risk (OR= 1.7; 95% CI 1.1–2.8), while those with
fewer attacks were not at higher risk (12).
The data collected in the Women’s Health study (5,130 migrain-
ous women) confirmed a higher risk ratio for female migraineurs
with at least 1 attack with aura per week, RR 4.25 (CI 95% 1.36–
13.29), compared to those that have fewer attacks, RR 1.90 (95%
CI 1.18–3.08) (13).
MIGRAINOUS INFARCTION
Migraine with aura may be a direct cause of migrainous infarction
(14) and the classification made by the International Headache
Society (IHS) in 2013 (15) defines it as “One or more migrain-
ous aura symptoms associated with an ischaemic brain lesion in
appropriate territory demonstrated by neuroimaging.” These lesions
occur during the course of a typical migraine attack with aura, in
a subject that has had previous attacks, with the difference that the
symptoms persist for >60 min.
The diagnostic criteria of migrainous infarction, recently
revised by the International Classification of Headache Disorders,
third edition (ICHD-III) (beta version, 2013) (15):
A. A migraine attack fulfilling criteria B and C.
B. Occurring in a patient with MA (cod.1.2) and typical of pre-
vious attacks except that one or more aura symptoms persists
for >60 min.
C. Neuroimaging demonstrates ischemic infarction in a relevant
area.
D. Not better accounted for by another diagnosis.
Large clinical series (14, 16) reported that the prevalence of
migrainous infarction varies between 0.5 and 1.5% of all IS,
ranging up to 10–14% of IS in young patients and shows a preva-
lent involvement of the posterior circulation territory, occurring
mostly in young females with MA.
SUBCLINICAL BRAIN LESIONS
WHITE MATTER LESIONS
A cross-sectional study on a population-based sample of Dutch
adults aged 30–60, aimed at comparing the prevalence of brain
infarcts and WMLs in migraine cases and controls, showed an
increased risk for high WML load only in women with migraine;
this risk increased along with an increase in attack frequency, but
was similar in patients with migraine with or without aura (5).
The population-based, case–control MRI Dutch study CAM-
ERA (6), enrolled 295 migraineurs and 140 controls, aged 20–
60, who were interviewed, given a physical examination and a
brain MRI scan. There was an increased independent risk of
clinically silent WMLs for female migraineurs (OR= 2.0; 95%
CI 1.0–4.1). The risk for WMLs was higher in those with more
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frequent attacks (≥1 attack/month, OR= 2.6; 95% CI 1.2–6.0),
whatever the migraine subtype and the effects of cardiovascular
risk factors. There were also an increased proportion of brainstem
hyperintense lesions (4.4 vs. 0.7%, p= 0.04) (6).
The vascular aging (EVA) study (17) on 116 migraine patients,
617 non-headache controls and 47 non-migraine headache
controls, reported an overall association of severe headache
with increasing volume of WMLs (41% of patients and 31%
of controls had a high WML load). This relationship was
not specific to migraine alone, but extended to non-migraine
headaches (17).
A recent systematic review and meta-analysis showed an
increased risk for WMLs only in MA patients (OR= 1.68; 95% CI
1.07–2.65), while no association was found for migraine without
aura (MO) patients (18).
Although WMLs have been associated with an increased risk
of cognitive decline, results from longitudinal studies show that
patients suffering from migraine (both MA and MO) are not
at increased risk of cognitive decline. The lack of association
between migraine and cognitive decline was not affected by gender,
education, baseline cognitive status, APOE or MTHFT genotype,
or medication use. Despite the associations observed between
migraine and structural brain lesions in some studies, strong evi-
dence of worse cognitive performance among migraineurs with
high-structural brain lesion load is lacking (17, 19).
SILENT INFARCT-LIKE LESIONS
Silent infarct-like lesions (ILLs) are MRI or CT signal abnor-
malities defined as non-mass brain parenchymal defects with the
same intensity as cerebrospinal fluid and without symptoms. The
distinction between cavitated infarction and dilated perivascular
spaces may be challenging and was mainly based on the diam-
eter >3 mm. However, although helpful, the threshold of 3 mm
is arbitrary and perivascular spaces of >3 mm are not a rare
finding (20).
The CAMERA study (6) reported an increased prevalence of
ILLs in the posterior circulation territory in migraineurs. The
majority (88%) of infratentorial ILLs had a vascular border zone
location in the cerebellum, their prevalence was different between
controls (0.7%), patients with MO (2.2%), and patients with MA
(7.5%) (OR= 13.7; 95% CI 1.7–112).
Overall, silent ILLs were reported as being more common in
migraineurs than in controls in the recent, aforementioned meta-
analysis (18). The association of ILLs was greater for MA than for
MO, but no association was found for MA (p= 0.52) and MO
(p= 0.08) compared to controls (18).
The progression of ILLs was determined by the AGES-Reykjavik
study (21), which evaluated the presence of ischemic lesions in a
total of 4,689 individuals, followed as from 1967, examined and
interviewed about migraine features and cardiovascular risk fac-
tors in midlife. They were given a brain MRI assessment between
2002 and 2006, after an average of 25 years from first examination,
12% of the participants had migraine. After adjusting for other
risk factors, MA had an increased RR for ischemic lesions at an
advanced age (adjusted OR= 1.4; 95% CI 1.1–1.8), there was an
association between MA and ischemic brain lesions in females,
with an adjusted OR of 1.9 (95% CI 1.4–2.6). Subjects with MA
had a 12-fold risk of ischemic WMLs than controls. There was no
increased risk in MO or non-migraine headache (21).
MIGRAINE AS A RISK FACTOR FOR HEMORRHAGIC STROKE:
THE EVIDENCE
The association between migraine and MA status with the risk
of hemorrhagic stroke (HS) in women was assessed in a prospec-
tive cohort study, analyzing data from participants in the Women’s
Health Study (22). A total of 27,860 women over 45 were stud-
ied, 5,130 were migraineurs and 40% had MA. A total of 85 HSs
were observed during the 13.6-year-follow-up, with no statisti-
cally significant overall difference between subjects with or without
migraine. However, there was a statistically significant increased
risk for females with active MA (OR= 2.25; 95% CI 1.11–4.54),
who had suffered attacks in the previous year. Four HSs per year
per 10,000 females are attributable to migraine, while migrainous
females without aura have no increased risk of HS (22).
Also, a population-based longitudinal cohort study from Tai-
wan supports an increased risk for HS in migraineurs. The study
enrolled 20,925 subjects with a diagnosis of migraine and 104,625
age- and sex-matched, randomly sampled migraine-free subjects.
During the 2-year-follow-up, 113 subjects (0.54%) in the migraine
group and 255 (0.24%) in the non-migraine group, developed
HS. The crude hazard ratio (HR) for developing HS in the
migraine group was 2.22 compared to the non-migraine group
(95% CI 1.78–2.77, p= 0.0001) and the adjusted HR was 2.13
(95% CI 1.71–2.67; p= 0.0001) after controlling for demographic
characteristics and comorbid medical disorders (23).
A recent meta-analysis (10) of 8 studies (4 case–control and 4
cohort studies), involving a total of 1,600 HS, showed that the
overall pooled adjusted effect estimate of HS in subjects with
any migraine vs. control subjects was 1.48 (95% CI 1.16–1.88;
p= 0.002). The 4 case–control studies had a pooled OR of HS of
1.41 (95% CI 1.09–1.82; p= 0.009), whereas the 4 cohort studies
had a pooled HR of 1.47 (95% CI 0.97–2.24; p= 0.068). The HS
risk in subjects with MA (1.62; 95% CI 0.87–3.03; p= 0.129) was
not significant. Compared with control subjects, the risk of HS
was greater in females with any type of migraine (1.55; 95% CI
1.16–2.07; p= 0.003) and in female migraineurs under 45 (1.57;
95% CI 1.10–2.24; p= 0.012) (Table 1).
Lastly, a case–control study reported that migraine is an inde-
pendent risk factor for aneurismal rupture (OR= 2.4; CI 95% 1.1–
5.1), even if, as headache a premonitory symptom of aneurismal
rupture, recall biases might have affected the study results (24).
HEADACHE AS A SYMPTOM ASSOCIATED WITH IS
The relationship between migraine and stroke is bi-directional
(25). Headache is associated with IS in 17–34% of patients (26) and
bears its own classification in the 2013 IHS classification [headache
attributed to IS (cerebral infarction) 6.1.1]. It is described as a
new headache developing simultaneously with or in close tem-
poral relationship to signs or other evidence of IS associated
with neuroimaging confirmation of ischemic infarction. It is
more frequently observed in posterior strokes (OR= 2.15 CI 95%
1.23–3.77; p= 0.0076). Medina et al. (27) reported that headache
accompanied the ischemic event in 59% of patients with a transient
ischemic attack (TIA) or stroke in the anterior circulation, and in
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75% of patients with posterior ischemia. Headache is present at
onset in 43–60% of cases, is persistent in 25–30%, and starts after
in 14–27% of ischemic events. Headache associated with IS is more
frequently observed in migraineurs (27), where it may sometimes
mimic a migraine attack, although the studies reporting headache
as a symptom of stroke are not recent and do not take into account
the HIS classification for a definite diagnosis of the headache type.
MIGRAINE AND VASCULAR RISK FACTORS
In the past, migraine has been associated with an unfavorable
cardiovascular risk profile and a higher risk for coronary artery
disease when stratified by the Framingham risk score (28). In a
population-based study carried out in the Netherlands, the cardio-
vascular risk profile of 620 adult migraineurs was compared to that
of non-migraineurs. The migraineurs were more likely to be smok-
ers (OR= 1.43; 95% CI 1.1–1.8), to have a parental history of early
myocardial infarction, and were less likely to be alcohol consumers
(OR= 0.58 95% CI 0.5–0.7). Furthermore, MA patients tended to
have high-blood pressure (OR= 1.76 95% CI 1.04–3.0), a worse
cholesterol profile (total cholesterol ≥240 mg/dL: OR= 1.43 95%
CI 0.97–2.1), and an earlier onset of coronary heart disease or
stroke (OR= 3.96; 95% CI 1.1–14.3), with a twofold probabil-
ity of having an elevated Framingham risk, resulting in a higher
cardiovascular risk profile (29).
The recent cross-sectional, population-based HUNT study
(30) assessed parameters such as blood pressure, body mass
index (BMI), serum total, and high-density lipoprotein choles-
terol in 44,098 subjects so as to calculate the Framingham 10-year
risk score for coronary death and myocardial infarction (30).
The authors reported an unfavorable cardiovascular risk pro-
file, as established by an elevated Framingham risk score, both in
migraine with (OR= 1.54; 95% CI 1.21–1.95) and without aura
(OR= 1.17; 95% CI 1.04–1.32) and in non-migrainous headache
(OR= 1.17; 95% CI 1.10–1.26). Interestingly, there was a con-
sistent rise in the Framingham risk score in line with a higher
headache frequency, suggesting that more frequent headaches
and long-term migraine may worsen the cardio-metabolic pro-
file in migraineurs, with a higher Framingham risk score and
risk of developing atherosclerosis, insulin-resistance, and meta-
bolic syndrome (31). The increased risk in the HUNT study on
non-migrainous headache and MO was accounted for by lifestyle
factors, such as low-physical activity, smoking, and a high BMI.
Conversely, these factors did not completely explain the elevated
risk in the MA patients, suggesting that other, peculiar mechanisms
underlie the elevated risk in MA (30).
On the other hand, more recently, the association between
migraine and vascular events has been demonstrated to be inde-
pendent from the common vascular risk factors, above all in the
young adult population with MA, although the smoking habit and
use of oral contraceptives most surely increase the IS risk in female
migraineurs (8, 32).
A multicentric Italian study (33) on 981 young adult IS patients
under 45, 50.7% females, was carried out to evaluate whether
the vascular risk profile variation had a predictive value on
the migraine subtype. Medical history included the presence of
headache attacks, any cardiovascular risk factors, the presence of a
PFO,theV-Leiden factor,and prothrombin mutations (coagulative
factor II mutation). The MA risk increased as the number of car-
diovascular risk factors decreased (OR= 0.50; 95% CI 0.24–0.99
for 2 factors or more) and the number of thrombophilic variants
increased (OR= 2.21; 95% CI 1.05–4.68 for carriers of at least 1 of
the 2), or in the presence of right-to-left shunt (RLS) (OR= 2.41;
95% CI 1.37–3.45). None of these factors influenced the risk of
MO. Therefore, there seems to be an inverse relationship between
migraine and vascular risk factors in stroke at a young age. Indeed,
young patients with IS had a low-cardiovascular risk profile and
a pro-coagulative state, while the presence of a PFO was associ-
ated to MA. In the discussion section, the authors propose, on the
basis of these data, that the small ischemic episodes caused by PFO
microembolisms may well give rise to a cortical spreading depres-
sion (CSD) and migraine attacks and that these episodes may
be favored by the presence of altered coagulation that increases
both the small embolisms and those with a symptomatic clinical
significance (33).
In agreement with these findings, another study demonstrated
a 1.5 greater IS risk (95% CI 1.1–2.0) in women aged 15–49 years
with probable MA (with visual aura), which was higher in those
with no history of hypertension, diabetes, or myocardial infarction
compared to women with no migraine. Women with probable MA
who were current cigarette smokers and current users of oral con-
traceptives had sevenfold higher odds of IS (95% CI 1.3–22.8) than
did women with MA who were non-smokers and did not use oral
contraceptive (11).
From another perspective, the Italian multicentric study MIR-
ACLE (34) was carried out on 2,973 patients with a diagnosis of
hypertension or migraine in a general practitioner setting, where
570/2,973 had both pathologies. The group with both patholo-
gies (where the onset of comorbidity occurred at about 45) had
a later onset of migraine, compared to the migraine-only group,
and an earlier onset of hypertension than the hypertension-only
group. This comorbidity group also had a higher prevalence of
cerebrovascular events than the group with only one factor: 4.4 vs.
0.7%, in the migraine-only group and 3.1% in the hypertension-
only group. There was a fivefold prevalence of a history of
stroke/TIA for the age group 40–49 in the comorbidity group,
compared to the hypertension-only group for the same age range
(4.8 vs. 0.9%) (34).
In summary, the current evidence suggests that, at a young
age, MA is directly associated with IS, in the presence of fewer
traditional cardiovascular risk factors which, conversely, seem
to increase the risk for IS in older migraineurs, worsening the
cardio-metabolic profile.
MIGRAINE AND OBESITY
Obesity is another relevant cardiovascular risk factor to have been
associated with migraine, especially with a higher frequency of
pain crises, although the studies assessing such a relationship
between migraine and obesity have shown conflicting results,
which might well be due to methodological differences (self-
reported BMI in some studies, direct measurement in others,
mainly in those confirming the association).
Bigal et al. (35) showed that, although migraine prevalence was
not associated with BMI, the proportion of subjects with severe
headache pain increased as did the BMI, doubling in the morbidly
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obese group (BMI ≥35 kg/m2) compared to the group with a
normal BMI (BMI 18.5–24.9 kg/m2). Indeed, a higher BMI was
directly correlated to a high number of headache crises (35).
Moreover, another study (36) reported that the prevalence of
“transformed” migraine ranged from 0.9% in normal weighted
subjects to 1.2% in overweight subjects (OR= 1.4; 95% CI 1.1–
1.8), 1.6% in obese subjects (OR= 1.7; 95% CI 1.2–2.4), and 2.5%
in severely obese subjects (OR= 2.2; 95% CI 1.5–3.2), implying
that obesity is likely to be a risk factor for “transformed” migraine.
Furthermore, for a BMI ≥35 kg/m2, an OR of daily migraine
of 3.11 (95% CI 1.12–8.67) was detected in women, along with
an increased risk of phonophobia and photophobia and decreased
risk of a unilateral pain characteristic and migraine aura, suggest-
ing that the association between BMI with migraine is limited to
migraine frequency and specific migraine features (37).
MIGRAINE AND CORONARY HEART DISEASE
Although three population studies have supported the relationship
between migraine, especially MA, and coronary heart disease, an
increased risk of cardiac events in migraineurs was not confirmed
by a meta-analysis.
The Women’s Health Study (38) demonstrated a more evi-
dent association between MA and both cardiovascular disease
and stroke in 27,519 female patients (3,577 migraineurs) with
an 11.9 year follow-up, stratified by the Framingham risk score
for coronary heart disease, in the presence of a low-Framingham
score. Female migraineurs with a low-Framingham score had an
OR of 3.88 (95% CI 1.87–8.08) for IS and 1.29 for myocardial
infarction (95% CI 0.40–4.21). The females with MA in the high-
risk group had an OR of 1.0 (CI 95% 0.24–4.14) for stroke, and
3.34 (95% CI 1.50–7.46) for myocardial infarction. Women with
MO did not have any increased risk of myocardial infarction or IS
in any of the Framingham risk score groups (38).
In the Atherosclerosis Risk in Communities Study, patients
with headache were roughly twice as likely to have a history of
angina than were controls and the MA group had the highest risk
score (39).
Furthermore, as part of the Physician’s Health Study, men with
any migraine (with or without aura) were reported to have at
increased risk for major cardiovascular disease (HR: 1.24; 95%
CI 1.06–1.46), a finding supported by a 42% increased risk of
myocardial infarction (40).
However, in the aforementioned meta-analysis by Schurks et al.
(8), which confirmed the increased IS risk in migraine, there
was neither statistically significant difference for the association
between any migraine and myocardial infarction: OR= 1.12 (CI
95% 0.95–1.32) nor for the association between migraine and
death due to cardiovascular events: OR= 1.03 (CI 95% 0.79–1.34).
Lastly, a population-based study found that after adjustments
for gender, age, disability, treatment, and vascular risk factors,
migraine remained significantly associated with myocardial infarc-
tion (OR= 2.2; 95% CI 1.7–2.8), stroke (OR= 1.5; 95% CI
1.2–2.1), and claudication (OR= 2.69; 95% CI 1.98–3.23) (41).
MIGRAINE AND PATENT FORAMEN OVALE
The association of migraine and the presence of PFO have
attracted a great deal of attention and study over the last few years.
Patent foramen ovale has been observed in approximately
40–60% of people with MA (42) as compared to about 25% of the
general population (43). A systematic review of literature, using
meta-analysis to combine the results of different studies showed
that the OR of PFO in patients with migraine compared with the
OR of PFO in a group of patients without migraine was 2.54 (95%
CI 2.01–3.08) (42).
Such an association between migraine and PFO is bi-
directional, since subjects with PFO have a fivefold higher risk
of suffering from migraine (44, 45). However, there are also data
pointing against the correlation between PFO and MA. The only
population-based study investigating the association between PFO
and migraine with or without aura was cross-sectional and found
no association (46). The limitations of this study are the use of
transthoracic echocardiography to evidence the PFO (which has a
low diagnostic accuracy in detecting atrial defects), the age group
was older for migraine patients and self-reporting of disease may
not be reliable (47).
A report documented that the occurrence of atrial shunts was
consistent with autosomal-dominant inheritance in some families
with MA (48). The presence of a PFO seems to run in fam-
ilies: siblings of stroke patients with PFO have a significantly
higher prevalence of PFO than do those without, for brothers
(OR= 3.64; p= 0.015) and for sisters (OR= 9.8 p< 0.01) (49).
Subjects with PFO and migraine have a higher probability of hav-
ing a family history of migraine than those who have migraine
alone without PFO.
Some theoretical pathophysiological mechanisms may be
involved in PFO leading to migraine. It has been observed that
small particles and air bubbles in animals may trigger CSD and,
therefore, there is a possibility that PFO may promote migraine
attacks in some patients. Moreover, vasoactive amines and other
compounds that are usually removed at a pulmonary level,
like prostaglandins, serotonin (pulmonary removal 85–95%),
angiotensin I not converting into angiotensin II and bradykinin,
may bypass the pulmonary filter through the PFO and trigger
migraine (50). However, if RLS is involved in the pathogenesis
of MA, then the degree of the RLS might be postulated to affect
the clinical picture of patients with aura and migraine headache.
Conversely, some data show that RLS does not seem to affect the
clinical manifestation of MA and that the extent of RLS fails to
correlate with the severity of the clinical picture of the disorder,
against the migraine/PFO nexus (51, 52).
Patients with migraine and a history of IS have ample
RLSs (53). The percutaneous closure of septal defects with a
left-to-right shunt has been associated with improvement of
migraine. Although non-randomized studies have documented
that migraine attacks frequency decrease after percutaneous clo-
sure of the RLS (54), to date, the only randomized study, i.e.,
Migraine Intervention with STARFlex Technology, MIST, carried
out on this topic, did not confirm these results, giving rise to
substantial controversy (55).
However, there are several limitations that should be taken into
consideration in these studies, including there being no control
group, the possible impact of incomplete closure of the atrial
shunt, the retrospective design, implicating recall bias, the placebo
effect that may lead to up to 70% reduction of attacks frequencies,
www.frontiersin.org October 2014 | Volume 5 | Article 193 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Guidetti et al. Migraine and stroke
the potential prophylactic effect of aspirin administered after PFO
closure.
Moreover, the risks involved in PFO closure must not be under-
estimated. Literature reports that up to 8% of transcatheter inter-
ventions may require surgical procedures to manage complications
(56). Therefore, it may be concluded that, currently, PFO closure
is not a recommended routine procedure to prevent migraine.
MIGRAINE AND CERVICAL ARTERY DISSECTION
A recent meta-analysis (57) has demonstrated that migraineurs
have a twofold risk of dissection of the cervical arteries (CAD)
(OR= 2.06; CI 95% 1.33–3.19). In a hospital-based prospective
case–control study, which assessed personal and family history of
migraine in 72 patients with CAD, 72 patients with cerebral infarct
unrelated to a CAD (non-CAD), and 72 control subjects, personal
history of migraine was significantly associated to CAD compared
to non-CAD (59.7 vs. 30.6%; OR= 3.14; 95% CI 1.41–7.01) and
controls (18.1%; OR= 7.41; 95% CI 3.11–17.64). As opposed to
MA, MO had a significantly higher frequency among those with
CAD than among those without (56.9 vs. 25.0%; OR= 3.91; 95%
CI 1.71–8.90) and controls (58).
One case–control study (59) on 313 patients with CAD vs.
controls clearly demonstrated that migraine was more frequently
observed in subjects with CAD than in controls (36 vs. 23%
OR= 2.15; 95% CI 1.48–3.14) and that there was a higher asso-
ciation for MA patients (23 vs. 12%, OR= 2.41; 1.53–3.80), with
females prevailing over males. Migraine was more common among
patients with CAD and stroke, than in stroke patients without CAD
(35.7 vs. 27.4%, p= 0.003) (60), in agreement with the hypothesis
that “migraine may represent a predisposing condition for cervical
artery dissection” (58).
MIGRAINE AND GENETIC PATHOLOGIES
Migraine has been observed to be a prominent feature in the
phenotype of several genetic vasculopathies and channelopathies
(44). Familial hemiplegic migraine (FHM) is due to mutations in
the CACNA1A gene, coding for the voltage-gated Cav2.1 calcium
channel α subunit (61). Transgenic knock-out mice with Cav2.1
voltage-gated Ca2+channel mutations were demonstrated to be
more prone to develop CSD (characterized by an intense depo-
larization of neuronal and glial membranes) and to have a higher
susceptibility to IS with a faster than average depolarization at
the artery occlusion and a quicker expansion of the infarction
core at diffusion MRI. Therefore, these mice showed more exten-
sive ischemic lesions and higher disabilities than did the control
mice (62).
Migraine with aura is the earliest manifestation of “cerebral
autosomal-dominant arteriopathy with subcortical infarcts and
leukoencephalopathy” (CADASIL), and is observed in about 30%
of cases. CADASIL, a disease belonging to a family of disorders
known as “leukodystrophies,” is a pathology caused by mutations
of the Notch 3 gene on chromosome 19, which codifies a trans-
membrane receptor, expressed almost exclusively by nervous and
vascular smooth muscle cells. There is a progressive degenera-
tion of the smooth muscle cells in the blood vessels due to the
accumulation of the Notch3 protein, observed as granular osmio-
phillic deposits at electron microscopy. The resulting damage
may increase the susceptibility to CSD (63). Migraine has been
observed in 44% of females with CADASIL and in 31% of males.
While there is a male preponderance for stroke: 74 vs. 57% for
females (64).
Susceptibility toward migraine is not only a feature of CADASIL
but is also present in retinal vasculopathy with cerebral leukody-
strophy (RVCL), in hereditary endotheliopathy with retinopathy,
nephropathy, and stroke (HERNS) as well as in hereditary infantile
hemiparesis retinal arteriolar tortuosity and leukoencephalopathy
(HIHRATL) (65). RVCL is a neuro-vascular syndrome, caused
by a mutation in the TREX1 gene, which starts with vision loss,
followed by cognitive disturbances, depression, and migraine.
An MRI investigation detected WMLs in the advanced stage.
HIHRATL is due to a mutation in the COL4a1 gene, encoding the
α1 chain of type 4 collagen. In the presence of this vasculopathy, the
cerebral vessels usually show a destruction of the basal membrane,
and enlargement of the endothelial cells, although the patho-
physiological mechanisms linking these genetic vasculopathies to
migraine are still unknown. However, common genetic suscep-
tibility, enhanced susceptibility to CSD, and vascular endothelial
dysfunction have been hypothesized to play a role (66, 67).
Lastly, another disease presenting stroke and migraine is the
syndrome of mitochondrial myopathy, encephalopathy, lactic aci-
dosis, and stroke (MELAS), caused by mutations in the mito-
chondrial DNA (68). Patients affected by MELAS usually present
prolonged MA attacks, indicating that some kind of energy
dysfunction may underlie migraine.
MIGRAINE AND AUTOIMMUNE PATHOLOGIES
Headache is the main symptom in giant cell arteritis or Horton’s
disease, but migraine, stroke, and loss of memory are frequent
symptoms in antiphospholipid syndrome or antiphospholipid
antibody syndrome, also known as Hughes syndrome (69, 70).
Conversely, recent data show that migraineurs have a significantly
higher prevalence of antiphospholipid antibodies, suggesting that
the presence of comorbidity between the two conditions (71).
Migraine is observed in 52% of cases of Sjögren’s syndrome.
Late onset of “migraine-like” episodes with prolonged sensori-
motor deficits and concomitant neuropsychiatric disease are
typical manifestations (72).
Migraine and headache of difficult classification are frequent
findings in systemic lupus erythematous (SLE), along with multi-
ple ischemic cerebral lesions (73). The question arises whether a
specific “lupus headache” exists as a separate entity. Such an issue
was addressed by Mitsikostas et al.’s study (74) of 2004. It pooled
data from 8/35 studies (controlled and uncontrolled) identified
in a literature search that used the IHS criteria and observed a
57.1% prevalence of headache of any type (migraine 31.7% and
tension-type headache 23.5%) in SLE patients. Pooled data from
seven controlled studies showed that the prevalence of all headache
types, including migraine, did not differ from controls. No clear
evidence was found for the concept of a “lupus headache” and nei-
ther specific pathogenetic mechanisms of headache in adult SLE
patients were identified, nor was any association between headache
and the disease status observed. Moreover, there was insufficient
evidence that headache is associated with anxiety and depression
in SLE (74).
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Headache is the most common manifestation in primitive vas-
culitis of the central nervous system (75, 76), where it is mostly
reported as a generic symptom.
PATHOPHYSIOLOGICAL REMARKS
The following possible explanations have been proposed for
comorbidity, i.e., the greater than coincidental association between
migraine and other pathological conditions, like IS, by Mannix
(77), Lipton and Silberstein (78):
1. One condition may cause the other.
2. There may be a common mechanism underlying both condi-
tions.
3. Genetic factors may cause a susceptibility to two or more
neurologic disorders.
4. Environmental factors may alter brain function in such a way
so that the likelihood of the occurrence of two neurological
disorders is increased.
Although rarely, an MA attack may directly cause an ischemic
event, the “migrainous infarction,” as in the first scenario. Con-
versely, headache is a symptom associated with IS in 17–34% of
patients (26) and bears its own classification in the IHS classi-
fication 2013 (coded as 1.4.3). Although migrainous infarction
accounts only for a minority of migraine-related strokes, it does
represent an useful model to highlight some pathophysiolog-
ical linking migraine to IS. Indeed, migraine may be consid-
ered a “neuro-vascular” disease, where the vascular consequences
of CSD (oligoemia and consequent increased intraparenchimal
vascular resistance) may combine with a coagulopathy (79). A
prolonged decrease in cerebral blood flow and neuronally medi-
ated vasodilatation cause sluggish flow in large intracranial ves-
sels during the aura migraine. Moreover, intravascular thrombo-
sis could be favored by neurogenically mediated inflammatory
responses caused by the release of vasoactive peptides, includ-
ing NO, activation of cytokines, and upregulation of adhesion
molecules (80).
However, most IS in migraineurs occur in the interictal phase,
suggesting that an indirect relationship between migraine and IS
(79), where the other three types of explanations of the comor-
bidity, according to Mannix, Lipton and Silberstein (77, 78) could
play a role.
Mainly, migraine and stroke may be related to each other by
shared pathophysiological mechanisms.
Indeed, endothelial dysfunction may be the pivotal “missing
link” between migraine and vascular disease (79). Indeed, some
studies have found that migraineurs have a lower endothelium-
dependent vasodilatation capacity than do to non-migraineurs
(81) due to a decreased NO bioavailability and an increased
oxidative stress in migraine. Therefore, even from this perspec-
tive, migraine may be regarded as a “vascular disorder.” However,
although endothelial dysfunction may be considered the final
common pathway of the traditional vascular risk factors, includ-
ing obesity, it is more likely to be directly related to the migraine
pathophysiology, on the basis of the evidence previously reported
that the association between migraine and vascular events seems
to be independent from the common vascular risk factors, at least
at young age (33).
As aforementioned, migraine increases the risk for CAD, which
is involved in a small proportion of strokes and mainly in young
subject. Indeed, some migraine patients have elevated serum elas-
tase levels, which may indicate abnormalities of the vessel walls and
predispose to dissection; conversely, some reports have described
CADs that trigger migraine attacks (57, 82, 83).
Patent foramen ovale has been supposed to one of the bio-
logical mechanisms linking migraine to stroke. However, this
migraine/PFO relationship might represent the result of a com-
mon genetic disposition leading, on the one hand, to migraine
and, on the other, to endocardiac alteration with persistence of
the foramen ovale (84) and, putatively, to artery wall laxity with
propensity to spontaneous artery dissection. Hence,genetic factors
could confer a susceptibility to migraine and stroke, as foreseen
in the third scenario, according to Mannix (77). Indeed, as previ-
ously reported, migraine and stroke are prominent clinical features
of the phenotype of several genetic vasculopathies (CADASIL,
HRNS, HIHRATL, RVCL), channelopathies (FHM), and mito-
chondrial myopathies (MELAS). Although these are rare disorders
and cannot justify most cases of migraine and stroke, they do, how-
ever, suggest that putative, still unknown genetic factors involved
in the structure and function of cortical-meningeal vessels and in
neuronal excitability regulation lie at the basis of such comorbid-
ity. Moreover, since anatomical variants of the circle of Willis have
been detected more frequently in migraineurs than in controls
and, particularly, posterior anomalies in MA, a “vascular mech-
anism” has been hypothesized where a dysregulation in cerebral
blood flow in regions supplied by the variant circle could lead to
CSD (85).
As to the role of environmental factors in the relationship
between migraine and stroke, migraine-specific drugs, e.g., ergot-
derivatives and triptans, have been questioned, due to the possi-
bility of their having adverse effects on the cerebral vasculature.
However, data on ergotamine are controversial. A case–control
study reported an increased risk of ischemic events in ergotamine
abusers (86), especially in those on other cardiovascular treat-
ments, while therapeutic dosages do not seem to affect the vascular
risk. No significant association has been found for the use of these
triptans in migraineurs and stroke incidence (87, 88).
Lastly, even acquired and genetic thrombophilic disorders have
been hypothesized to contribute to the migraine–stroke comor-
bidity. Debate is still ongoing as to hyperhomocysteinemia, where
some studies report increased homocysteine levels in migraineurs,
particularly in MA, and an association with the C677 polymor-
physms of the methylenetetrahydrofolate reductase mutations
(MTHFR) gene (89). Moreover, there is a high incidence of throm-
bophilia in individuals with MA and PFO, in particular, in those
with MTHFR, protein C, and protein S deficiency and the pres-
ence of thrombophilia increases the indication for closure (53, 90).
However, further studies are needed to clarify this issue.
MIGRAINE, HEMORRHAGIC STROKE, AND STRESS
Several hypotheses have been formulated as to the mechanisms
that link hemorrhage to migraine and include the presence, in
migraineurs, of a vessel wall pathology (a dysfunction in the
endothelial cells, an increase in the vessel resistance), a platelet
dysfunction, moreover, the presence of arteriovenous malforma-
tions, though these are rare causes of migraine (57, 82, 83).
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Based on some initial evidence as to an association between
stroke and stress on the one hand, and on the well-known, complex
relationship between migraine and stress (91), on the other, even
stress may play a role in increasing the risk for HS in migraine.
The case–control study INTERSTROKE (92), carried out in 22
countries on a total of 3,000 stroke cases (78%, with IS; 22%,
with intracerebral HS), and 3,000 controls, demonstrated a sta-
tistically significant association between ictus and psychosocial
stress (OR= 1.30 95% CI 1.06–1.60) and depression (OR= 1.35,
95% CI 1.10–1.66). Also, the longitudinal population-based study,
Chicago Health and Aging Project (93), carried out in Chicago
with individual interviews on a population of African Americans
and non-Hispanic white subjects aged ≥65, showed a statistically
significant association, corrected for risk factors, between stress
and stroke mortality. This was confirmed, at secondary analysis
for stroke subtypes, for HS (OR= 1.70; 95% CI 1.28–2.25). Fur-
thermore, two case–control studies (94, 95) have reported that
even psycho-physical stress and self-perceived psychological stress
are associated to an increased risk of IS, supporting a possible
role for stress as a risk factor for stroke. Hence, in our hypothesis,
stress consequent to pain in migraine, especially when chronic,
may represent a “missing link” in the complex interplay between
migraine and stroke (Figure 1),where a higher headache frequency
and long-term migraine may worsen the cardio-metabolic profile
in migraineurs, with a higher risk of developing atherosclerosis,
insulin-resistance,and metabolic syndrome (31). However, further
studies are required to support this hypothesis.
CLINICAL MANAGEMENT IMPLICATIONS
Migraine patients are followed-up in headache centers that mainly
aim at pain attack prevention, while less attention is usually paid to
cardiovascular prevention. Conversely, the comorbidity between
migraine and stroke should be carefully considered in the clinical
management of migraine patients, mainly for treatment regimes.
As MA is now recognized as a well-defined risk factor for IS,
patients given an MA diagnosis should be screened for other, con-
comitant vascular risk factors, as recently suggested by Sacco et al.
(96), especially if not young and/or in the presence of WMLs at
neuroimaging. However, migraineurs with a normal neurologic
examination do not require routine MRI. Modifiable vascular risk
factors should be carefully treated, in migraineurs, with proper
pharmacological and, if need be, behavioral strategies, to reduce
the global burden of the patient’s vascular risk. As good clinical
practice suggests in all cases of comorbidities, it is advisable to
choose drugs that are potentially useful for both migraine pro-
phylaxis and the treatment of the associated conditions affecting
the vascular risk. For example, in the case of hypertension, the use
of angiotensin-converting enzyme inhibitors, may be a reasonable
choice, considering that such drugs have yielded some preliminary
evidence, on the one hand, of a reduction of the risk of vascu-
lar events in normotensive subjects, and on the other, have been
of benefit in migraine prophylaxis (96). However, the American
Heart Association/American Stroke Association 2011 guidelines
(97) for the primary prevention of the IS state that “because there
is an association between migraine frequency and stroke risk, treat-
ments to reduce migraine frequency might be reasonable, although
there are no data showing that this approach would reduce the risk
of a first stroke.” Lastly, the use of oral contraceptives should be
discouraged in all female patients suffering from MA and, in sub-
jects with MO, in the presence of concomitant vascular risk factors,
thrombophilic conditions (96), and/or being over 35.
CONCLUSION
Migraine, mostly MA and IS are interconnected by a complex bi-
directional relationship. Migraineurs have about a twofold higher
risk of IS and although this risk increase has been well-defined
for MA, this does not apply to MO. The risk is further increased
by female gender, being under 45, smoking, and/or being on
Old age
CAD - PFO - Thrombophilic factors
Stroke
Cerebrovascular Disease
White Matter Lesions
Chronic pain Traditional vascular risk factors
Mi
gra
ine
Young age
Stress
FIGURE 1 |The migraine-stroke interplay: pathophysiological connections.
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oral contraceptive. There is also an increased independent risk
of clinically silent WMLs for female migraineurs.
Migraine is also associated with increased risk of HS, mostly in
young women.
Although the interplay between migraine, IS, and cardiovas-
cular risk factors is manifold and controversial, it is likely that
migraine is directly associated with IS at a young age, where there
seems to be an inverse relationship between MA and the tradi-
tional vascular risk factors. Conversely, in older migraineurs, the
cardiovascular risk factors may play a role in linking migraine
to stroke, based on the finding that long-term, chronic migraine
seems to worsen the cardio-metabolic profile in migraineurs by
mechanisms, which might include chronic stress induced by pain,
even if this hypothesis deserves confirmation.
The relationship between migraine and stroke could also
involve PFO, CAD, and genetic vascular pathologies, whereas such
conditions may share with migraine common genetic predispos-
ing traits. Although the prevalence of PFO has been proven to be
significantly higher in patients with MA than in healthy controls,
the relationship between migraine and PFO remains controver-
sial and PFO closure is not a recommended procedure to prevent
migraine.
Lastly, although the pathophysiological mechanisms underly-
ing the comorbidity between migraine and IS remain to be fully
elucidated, the evidence linking MA to IS is such that patients
with MA should be screened for other concomitant conventional
vascular risk factors and treated accordingly.
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